TECHNICAL DATA SHEET

CD19 (4G7)

Туре	Size	Catalog number
Unconjugated	100μg	102901
	500μg	102903
FITC	25 tests	102914
	100 tests	102915
	200 tests	102916
PE	25 tests	102924
	100 tests	102925
	200 tests	102926
APC	25 tests	102944
	100 tests	102945
	200 tests	102946
PerCP	25 tests	102934
	100 tests	102935
	200 tests	102936
PE-CF594	25 tests	1029204
	100 tests	1029205
	200 tests	1029206
PE-Cyanine7	25 tests	102984
	100 tests	102985
	200 tests	102986
PerCP-Cyanine5.5	25 tests	102964
	100 tests	102965
	200 tests	102966
iFluor™ 647	25 tests	1029124
	100 tests	1029125
	200 tests	1029126
iFluor™ 700	25 tests	1029194
	100 tests	1029195
	200 tests	1029196
iFluor™ 488	25 tests	1029114
	100 tests	1029115
	200 tests	1029116
APC-iFluor™ 700	25 tests	1029174
	100 tests	1029175
	200 tests	1029176
Biotin	100μg	102951

[❖] iFluor is a trademark of AAT Bioquest, Inc.

Antigen: CD19

Immunogen: Human CCL (chronic lymphocytic leukemia) cells

Host/Isotype: Mouse, IgG1,κ

Reactivity: Human

Purity: >90% pure tested via polyacrylamide gel electrophoresis (PAGE)

Formulation: PBS, pH7.2, 0.09%NaN₃ (unconjugated, Biotin)

PBS, pH7.2, 0.09% NaN₃ and 0.2% (w/v) BSA (conjugated)

Storage: Store at 2-8°C and protected from prolonged exposure to light. **Do not freeze.**

Applications: Flow Cytometry



TECHNICAL DATA SHEET

Application Information

Each lot of these antibodies has been pre-titrated and tested by flow cytometric analysis of human PBMCs such that $0.5\mu g$ (unconjugated, Biotin) or $5\mu l$ (conjugated) of these products are sufficient for staining 1 million cells in a $100\mu l$ staining volume or $100\mu l$ of whole blood. It is recommended to titrate antibody reactivity empirically for optimal performance.

Antigen Information

The clone 4G7 recognizes a 90-kDa CD19 antigen that is present on human B lymphocytes. The CD19 antigen is present on approximately 7 to 23% of human peripheral blood lymphocytes at all stages of B cell maturation but is lost on terminally differentiated plasma cells. CD19 does not react with resting or activated T lymphocytes, granulocytes, or monocytes.

References

- 1. Kugler M, et al. 2009. Protein Eng Des Sel. 22:135.
- 2. Lemmers B, et al. 2000. Leukemia. 14:2103.
- 3. Meeker TC, et al. 1984. Hybridoma. 3:305.
- 4. Strickler JG, et al. 1988. Cancer. 61:1782.

Terms and Conditions

This product is for research use only (RUO) and not intended for diagnostic testing.